OCSL Stock Analysis: Oaktree Specialty Lending | NASDAQ
Asset Management | NASDAQ, USA | Market Cap: 1.120m USD | 12M Return: 6.3% | US67401P4054 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.30M
EPS Trend: -97.6%
Qual. Beats: 0
Rev. Trend: 4.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Oaktree Specialty Lending Corporation (OCSL) is a business development company (BDC) that provides debt and equity capital to small and mid-sized companies, primarily in North America. It focuses on middle market lending, including first and second lien debt, mezzanine financing, bridge loans, and preferred equity, with investments ranging from $5 million to $75 million in companies with enterprise values between $20 million and $150 million and EBITDA between $3 million and $50 million. The firm serves a broad range of sectors, including business services, healthcare, education, manufacturing, software, consumer and retail, media, pharmaceuticals, and real estate, and typically seeks to act as a lead investor in its portfolio companies.
BDCs are regulated under the Investment Company Act of 1940 and are generally required to distribute the majority of their taxable income to shareholders, which influences their typical appeal to income-focused investors. Oaktree Specialty Lending operates as part of the broader asset management industry, with Oaktree Capital Management serving as its external investment adviser.
- Floating-rate loan portfolio gains from Fed rate outlook shifts
- Middle market credit quality pressures drive net asset value changes
- Dividend coverage tightens as spread compresses on borrowing costs
| Net Income: 44.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.76 > 1.0 |
| NWC/Revenue: -133.0% < 20% (prev 74.66%; Δ -207.6% < -1%) |
| CFO/TA 0.05 > 3% & CFO 142.4m > Net Income 44.4m |
| Net Debt (1.45b) to EBITDA (248.4m): 5.82 < 3 |
| Current Ratio: 0.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.1m) vs 12m ago 0.0% < -2% |
| Gross Margin: 86.27% > 18% (prev 22.69%; Δ 63.58% > 0.5%) |
| Asset Turnover: 9.59% > 50% (prev 5.32%; Δ 4.27% > 0%) |
| Interest Coverage Ratio: 1.44 > 6 (EBIT TTM 147.2m / Interest Expense TTM 102.5m) |
| A: -0.13 (Total Current Assets 62.9m - Total Current Liabilities 434.0m) / Total Assets 2.86b |
| B: -0.31 (Retained Earnings -885.1m / Total Assets 2.86b) |
| C: 0.05 (EBIT TTM 147.2m / Avg Total Assets 2.91b) |
| D: 0.94 (Book Value of Equity 1.38b / Total Liabilities 1.48b) |
| Altman-Z'' = -0.54 = B |
As of August 13, 2026, the stock is trading at USD 12.74 with a total of 432,663 shares traded. Over the past week, the price has changed by +5.64%, over one month by +5.90%, over three months by +8.24% and over the past year by +6.25%.
Current recommended Stop Loss: 12.20 (which is 4.2% or 1.7 ATR below the current price).
Oaktree Specialty Lending has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold OCSL.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.5 | -1.9% |
P/E Trailing = 20.5161
P/E Forward = 9.9404
P/S = 3.8341
P/B = 0.8101
P/EG = 0.9343
Revenue TTM = 279.1m USD
EBIT TTM = 147.2m USD
EBITDA TTM = 248.4m USD
Long Term Debt = unknown (none)
Short Term Debt = 96.8m USD (from shortTermDebt, last fiscal year)
Debt = 1.49b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 1.45b USD (calculated: Debt 1.49b - CCE 39.9m)
Enterprise Value = 2.57b USD (1.12b + Debt 1.49b - CCE 39.9m)
Interest Coverage Ratio = 1.44 (Ebit TTM 147.2m / Interest Expense TTM 102.5m)
EV/FCF = 18.03x (Enterprise Value 2.57b / FCF TTM 142.4m)
FCF Yield = 5.55% (FCF TTM 142.4m / Enterprise Value 2.57b)
FCF Margin = 51.02% (FCF TTM 142.4m / Revenue TTM 279.1m)
Net Margin = 15.92% (Net Income TTM 44.4m / Revenue TTM 279.1m)
Gross Margin = 86.27% ((Revenue TTM 279.1m - Cost of Revenue TTM 38.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev 86.31%)
Tobins Q-Ratio = 0.90 (Enterprise Value 2.57b / Total Assets 2.86b)
Interest Expense / Debt = 6.89% (Interest Expense 102.5m / Debt 1.49b)
Taxrate = 0.68% (304k / 44.7m)
NOPAT = 146.2m (EBIT 147.2m * (1 - 0.68%))
Current Ratio = 0.14 (Total Current Assets 62.9m / Total Current Liabilities 434.0m)
Debt / Equity = 1.08 (Debt 1.49b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 5.82 (Net Debt 1.45b / EBITDA 248.4m)
Debt / FCF = 10.16 (Net Debt 1.45b / FCF TTM 142.4m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.53% (Net Income 44.4m / Total Assets 2.86b)
RoE = 3.14% (Net Income TTM 44.4m / Total Stockholder Equity 1.42b)
RoCE = 6.07% (EBIT 147.2m / Capital Employed (Total Assets 2.86b - Current Liab 434.0m))
RoIC = 4.99% (NOPAT 146.2m / Invested Capital 2.93b)
WACC = 7.28% (E(1.12b)/V(2.61b) * Re(7.86%) + D(1.49b)/V(2.61b) * Rd(6.89%) * (1-Tc(0.01)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.02 | Cagr: 4.51%
[DCF] Terminal Value 73.10% ; FCFF base≈177.2m ; Y1≈155.4m ; Y5≈125.6m
[DCF] Fair Price = 6.46 (EV 2.02b - Net Debt 1.45b = Equity 568.8m / Shares 88.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -97.60 | EPS CAGR: -17.19% | SUE: 0.29 | # QB: 0
Revenue Correlation: 4.90 | Revenue CAGR: 1.36% | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.34 | Chg30d=-2.05% | Revisions=-50% | Analysts=6
EPS current Year (2026-09-30): EPS=1.50 | Chg30d=+0.45% | Revisions=-25% | GrowthEPS=-14.6% | GrowthRev=-10.0%
EPS next Year (2027-09-30): EPS=1.35 | Chg30d=-1.36% | Revisions=-25% | GrowthEPS=-10.0% | GrowthRev=-0.5%
[Analyst] Revisions Ratio: -62% (up=0, down=5)